TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05215145

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baby Navigator Bundle
Description: The Baby Navigator Bundle includes 1) Baby Navigator, an online collection of resources: videos, growth charts, milestones, short articles, checklists, tools, and tips to help families promote early learning. Tools are customized to the child's age (in months). Baby Navigator can be found at https://babynavigator.com. 2) Social Communication (SoCo) Growth Charts is a self-guided app for parents of babies from birth to 24 months. Parents can watch video clips of early milestones and chart their child's social communication development. 3) Baby Navigator Webinars are held twice a month. Parents can learn how to support their child's growth from birth to 24 months. Content and videos focus on social communication milestones. Expert-led sessions cover a range of topics: gestures and sounds babies need to learn to talk, everyday activities that encourage learning, getting ahead of the Terrible Twos, and how Baby Navigator can help families.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baby Navigator Bundle + Individual-ESI
Description: Continued Baby Navigator Bundle. Addition of ESI mobile coaching. ESI program planning entails identifying goals and objectives for the child and teaching strategies and supports for parents. Each session includes the following components: 1) setting the stage to develop that session's agenda and gather updates; 2) intervention implementation that must include the following steps to coach the parent: a) review the objective, b) use modeling, guided/caregiver practice, or video review to teach the strategy, c) provide specific feedback to the parent, and d) problem solving and plan for next time; steps a-d are repeated for 3-5 activities per session; and 3) summarize plans for parent implementation between sessions. Families are also invited to and guided through the Autism Navigator How-To Guide for Families online course.
Study: NCT05006040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Closed Loop System
Description: Participants will utilize the Tandem Control-IQ Professional Hybrid Closed Loop artificial pancreas system \[25, 26\]. This device consists of the Dexcom G6 Continuous glucose monitor (or a more recent interoperable CGM), the Tandem t:slim X2 continuous subcutaneous insulin infusion pump, and the Control-IQ professional hybrid closed loop control algorithm. The CGM is generally replaced by parents or patients and then replaced after sensor expiration or if it falls off. This CGM, like all future iCGMs, is factory calibrated and approved for direct dosing of insulin. In addition, while the system is in use, patients will conduct blood glucose level checks at least four times a day with a fingerstick and calibrate the CGM if the measurements differ by more than 20 mg/dL of fingerstick blood glucose level. The t:slim X2 insulin pump delivers rapid acting insulin via a subcutaneous cannula which is placed by parents or patients and then replaced every 3 days \[30\].
Study: NCT05222711

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of the PICO(TM) monitoring device
Description: The aim is to record if the outcome (referral or not) is influenced by the results of the parameters and/or the ECG.
Study: NCT06001008

Intervention type: OTHER
Intervention: PQA
Description: PQA is a questionnaire consisting of 16 questions developed to measure the quality of anesthesia service received by patients based on their experiences. Patients will be asked to answer questions by the researcher 24 hours after surgery.
Study: NCT06265415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol
Description: it contains both selective, competitive, alpha1-adrenergic antagonism and non-selective, competitive, beta-adrenergic (B1 and B2) blocking activity in a single agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerine
Description: a nitric oxide donor with low oral bioavailability and a very short half-life, has a potent venodilator effect in low doses and affects arterial tone at high doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: dihydropyridine calcium channel blocker. Its main uses are as an antianginal and antihypertensive
Study: NCT04906876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel as a 60-minute IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel as a 60-minute IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9-ING-41
Description: 9-ING-41 as an IV infusion over 1-4 hours twice weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9-ING-41
Description: 9-ING-41 as an IV infusion over 1-4 hours twice weekly
Study: NCT05600023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Description: Nitrofurantoin has been found to successfully eradicate gram-negative bacteria such as Enterococcus faecalis that one of the most important bacteria in endodontic lesions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double Antibiotic
Description: DAP is a combination of two antibiotics which are ciprofloxacin and metronidazole
Study: NCT06055309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis (up to three doses)
Description: a dose of cannabis will be baked into brownies
Study: NCT06009588

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: self-expandable valves
Description: patients undergoing TAVR use self-expandable valves

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balloon-expandable valves
Description: patients undergoing TAVR use balloon-expandable valves
Study: NCT06143462

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Include anti-dizziness medications, diuretics, or hormone therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Include comprehensive health education, fall prevention and lifestyle adjustments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vestibular rehabilitation
Description: Encompass office-based sessions of vestibular rehabilitation treatment once weekly, supplemented by home-based exercises conducted two or three times daily for the remaining duration of the study.
Study: NCT06445127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: A non-invasive, non-contrast, renal MRI will be performed.
Study: NCT04635774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: 40 IU via four activations of an intranasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Four activations of an intranasal spray containing placebo (normal saline).
Study: NCT05313373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: In addition to the routine procedure, virtual reality glasses will be applied to the women in the virtual reality group of the research. Virtual reality glasses is a device that works on compatible smart mobile phones. After being taken to the gynecological table for the HSG procedure, the women included in the experimental group will be made to watch a video lasting an average of 10 minutes with virtual reality glasses until the procedure is completed. While watching the video, the relaxing music of the video will be played.
Study: NCT04642612

Intervention type: DEVICE
Intervention: TCD Measurement
Description: CBFV measurements will be acquired continuously with the patient supine and the head neutral. Analysis of CBFV measurements will be undertaken at 3 timepoints:~1. Patient awake and supine in the holding area~2. After sedation~3. After interscalene nerve block
Study: NCT04483973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ebselen
Description: Glutathione peroxidase mimetic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ebselen
Description: Glutathione peroxidase mimetic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo containing excipients
Study: NCT05271071

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided piriformis muscle and gluteus maximus muscle lidocaine injection
Description: Ultrasound guided piriformis muscle (piriformis syndrome) and gluteus maximus muscle 5 ml %1 lidocaine injection

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided piriformis muscle and gluteus maximus muscle lidocaine injection
Description: Ultrasound guided piriformis muscle (piriformis syndrome) and gluteus maximus muscle 5 ml %1 lidocaine injection
Study: NCT05646693

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Drusen Mega®
Description: It consists of a dietary supplement composed of Vitamin C 60.0mg, Vitamin E 30.0mg, Zinc 12.5mg, Copper 1.0mg, Astaxanthin 4.0mg, Zeaxanthin 2.0mg, Lutein 10.0mg and Omega 3 Acids 500.0mg. It is suggested to consume one capsule per day, preferably with food. This supplement is indicated for nutritional deficiencies and in patients with ophthalmological pathologies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: It consists of a drug capsule composed of Sertraline Hydrochloride 50mg. In adults it is suggested to consume one to four capsule(s) per day, administering (preferably) the highest dose in the evening, before going to bed. This drug is indicated in the treatment of depressive states with anxiety or moderate to severe agitation, which are accompanied by tension, excitement, insomnia, obsessive and hypochondriac traits. It is also indicated in obsessive-compulsive disorder, panic attacks, stress disorder, post-traumatic disorder, social anxiety disorder and used to relieve the symptoms of premenstrual dysphoric disorder.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sertraline
Description: It consists of a drug capsule composed of Sertraline Hydrochloride 50mg. In adults it is suggested to consume one to four capsule(s) per day, administering (preferably) the highest dose in the evening, before going to bed. This drug is indicated in the treatment of depressive states with anxiety or moderate to severe agitation, which are accompanied by tension, excitement, insomnia, obsessive and hypochondriac traits. It is also indicated in obsessive-compulsive disorder, panic attacks, stress disorder, post-traumatic disorder, social anxiety disorder and used to relieve the symptoms of premenstrual dysphoric disorder.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It consists of a placebo capsule composed of Magnesium Oxide 100mg. This component is inert in the dose at which it will be administered.
Study: NCT05603143

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Obeldesivir Placebo
Description: Placebo tablets administered orally without regard to food.
Study: NCT06442423

Intervention type: DRUG
Group type: OTHER
Intervention: Psilocybin
Description: Psilocybin will be administered in an opaque, size 2 gelatin capsule with approximately 180 ml of water to be orally ingested at Visit 5. The dose of psilocybin will be 25 mg.This is an open-label clinical trial with a single treatment arm. This is an open-label clinical trial with no blinding.
Study: NCT05085366

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1647
Description: Lyophilized product that is reconstituted with 0.9% sodium chloride (normal saline)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study: NCT06479135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navtemadlin
Description: Navtemadlin is an investigational MDM2 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Navtemadlin placebo
Description: Navtemadlin placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib is a janus kinase 1/2 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruxolitinib
Description: Ruxolitinib is a janus kinase 1/2 inhibitor
Study: NCT04398316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Iv
Description: 2 mg/kg over 5 minutes
Study: NCT06135064

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diadem
Description: The device delivers low-intensity ultrasonic waves into specified brain targets.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Diadem
Description: The device delivers low-intensity ultrasonic waves into specified brain targets.
Study: NCT04398316

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HYDROmorphone Injection
Description: 1 mg over 5 minutes
Study: NCT06396559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pre test-post test
Description: The mobile application will be installed on the mobile devices of student nurses and its effectiveness will be tested.
Study: NCT05613127

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boryung Hepatitis A Vaccine Pre-Filled Syringe Inj. 0.5 mL
Description: Dosage and administration: pre-iflled syringe, IM injection of 0.5mL will be given for 2 times with 6-months interval.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HAVRIX 720 Junior 0.5 mL
Description: Dosage and administration: pre-filled syringe, IM injection of 0.5mL will be given for 2 times with 6-months interval.
Study: NCT05853965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin, Venetoclax
Description: Belantamab mafodotin (IV) Venetoclax (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin, Venetoclax
Description: Belantamab mafodotin (IV) Venetoclax (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin, Venetoclax
Description: Belantamab mafodotin (IV) Venetoclax (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin, Venetoclax
Description: Belantamab mafodotin (IV) Venetoclax (PO)
Study: NCT05192473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse Intravascular Lithotripsy System
Description: Treatment with Pulse Intravascular Lithotripsy System
Study: NCT05748197

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADCLEC.syn1 CAR T cells
Description: There are 4 planned flat-dose levels: 25 × 10\^6, 75 × 10\^6 , 225 × 10\^6 , and 450 × 10\^6 CAR T cells and 1 de-escalation dose: 10 × 10\^6 CAR T cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning chemotherapy
Description: Fludarabine 30 mg/m2 daily for 3 days and cyclophosphamide 500 mg/m2 daily for 3 days.
Study: NCT05907590

Intervention type: OTHER
Intervention: Interoceptive accuracy measurement
Description: Interoceptive accuracy will be measured using the Respiratory Occlusion Discrimination Task (ROD task; Van Den Houte et al., 2021). The ROD task measures how good subjects are at distinguishing the lengths of short (max 620 milliseconds) inspiratory occlusions (or respiratory interruptions).

Intervention type: OTHER
Intervention: Interoceptive accuracy measurement
Description: Interoceptive accuracy will be measured using the Respiratory Occlusion Discrimination Task (ROD task; Van Den Houte et al., 2021). The ROD task measures how good subjects are at distinguishing the lengths of short (max 620 milliseconds) inspiratory occlusions (or respiratory interruptions).

Intervention type: OTHER
Intervention: Interoceptive sensibility measurement
Description: Interoceptive sensibility will be measured using two self-report questionnaires, the Interoceptive Sensitivity and Attention Questionnaire (ISAQ; Bogaerts et al., 2022) and the the Three-domain Interoceptive Sensations Questionnaire (THISQ; Vlemincx et al., 2021)

Intervention type: OTHER
Intervention: Interoceptive sensibility measurement
Description: Interoceptive sensibility will be measured using two self-report questionnaires, the Interoceptive Sensitivity and Attention Questionnaire (ISAQ; Bogaerts et al., 2022) and the the Three-domain Interoceptive Sensations Questionnaire (THISQ; Vlemincx et al., 2021)

Intervention type: OTHER
Intervention: Interoceptive awareness measurement
Description: Interoceptive awareness will be measures using a visual analogue scale (VAS)
Study: NCT05038124

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative Stereotactic Body Radiotherapy (SBRT)
Description: Target lesions will be treated with preoperative SBRT consisting of biologically effective dose (BED10) of 50.4 - 81.6 Gy delivered in either three fractions or a single fraction.
Study: NCT06089629

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lingual frenuloplasty
Description: Surgical release of ankyloglossia with suture reorientation of the wound to improve lingual mobility, done under local or general anesthesia
Study: NCT05875207

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based practice
Description: Physical therapists who are randomized to this arm will receive mindfulness training. This training will teach physical therapists to use the following with their patients: 1) use mindfulness to strengthen self-regulation of habitual and compulsive opioid use, and to mitigate pain by reinterpreting these experiences as innocuous sensory information, 2) use reappraisal to reframe stressors and maladaptive thoughts to decrease negative emotions and engender meaning in life, 3) use savoring of pleasant events and pleasurable sensations to enhance positive emotions and reward and, 4) to integrate mindfulness, reappraisal and savoring with evidence-based physical therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based practice
Description: Physical therapists who are randomized to this arm will receive mindfulness training. This training will teach physical therapists to use the following with their patients: 1) use mindfulness to strengthen self-regulation of habitual and compulsive opioid use, and to mitigate pain by reinterpreting these experiences as innocuous sensory information, 2) use reappraisal to reframe stressors and maladaptive thoughts to decrease negative emotions and engender meaning in life, 3) use savoring of pleasant events and pleasurable sensations to enhance positive emotions and reward and, 4) to integrate mindfulness, reappraisal and savoring with evidence-based physical therapy.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control/Standard Physical Therapy
Description: Physical therapists randomized to this arm will receive no additional training and will provide standard care to patients with chronic musculoskeletal pain and long-term opioid treatment. Patients with chronic musculoskeletal pain and long-term opioid treatment who seek care from a physical therapist in this arm will be approached to participate in the study. If eligible and willing to participate in the study they will be asked questions about their pain and opioid use before and after treatment. We plan on enrolling 2 patients for each physical therapist.
Study: NCT04278989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-tumor B
Description: 1,200 mg, three times a day for seven to 28 days (dependent on scheduled surgery).
Study: NCT05907590

Intervention type: OTHER
Intervention: Interoceptive awareness measurement
Description: Interoceptive awareness will be measures using a visual analogue scale (VAS)
Study: NCT05929430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness program
Description: Six weeks mindfulness program. The program is explained in arm descriptions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness program with Virtual Reality
Description: Six weeks mindfulness program. The program is explained in arm descriptions.
Study: NCT06049654

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NVT ALLEGRA TAVI System TF
Description: Transcatheter aortic valve implantation of a NVT ALLEGRA TAVI System TF in patients with severe haemodynamical valve deterioration of a biological aortic valve implanted surgically

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EDWARDS SAPIEN 3 or SAPIEN ULTRA SYSTEM
Description: Transcatheter aortic valve implantation of an EDWARDS SAPIEN 3 SYSTEM in patients with severe haemodynamical valve deterioration of a biological aortic valve implanted surgically
Study: NCT05608083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEARTS classes
Description: HEARTS teaches autistic adults about friendship and healthy dating relationships. HEARTS is 6-sessions long and meets weekly over zoom. Each session is 90 minutes long.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online discussion group
Description: A 90-minute discussion group will meet online weekly for 6 weeks to discuss friendships and healthy dating relationships for autistic adults.
Study: NCT06435832

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Absorbable Gelatin
Description: After tooth extraction, only saline irrigation was applied and a absorbable gelatin sponge was placed in the socket.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: After tooth extraction, after irrigation with saline, 2% chlorhexidine gel was absorbed into gelatin sponges and placed into the socket.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: Tranexamic acid 50mg/ml for injection after saline irrigation after tooth extraction solution into gelatin sponges was applied to the socket after it was cured.
Study: NCT05907590

Intervention type: OTHER
Intervention: Proprioceptive accuracy measurement during postural control
Description: The effect of muscle vibration on center of gravity displacement (center of pressure or COP) will be examined. Muscle vibration of the m. triceps surae (ankle muscles) and the lumbar multifidus (back muscles) (Johanson et al., 2011; Brumagne et al., 2008; Claeys et al., 2011; Cleays et al., 2015) will be used to examine the role of proprioception during postural control.
Study: NCT05150990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Older adults (residents of senior living communities) will engage in four 20-minute virtual reality activities (via the Rendever platform) with their adult child each week for 4 consecutive weeks. The 4 sessions will include immersive virtual adventures (e.g., bucket list travel) and reminiscence activities (e.g., virtual life story). Adult children will be participating remotely from their own homes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Chat
Description: Older adults (residents of senior living communities) will engage in four 20-minute video chat sessions (via the Zoom platform) with their adult child each week for 4 consecutive weeks. Adult children will be participating remotely from their own homes.